Podcasts about Assay

Purepoint Uranium Group CEO Chris Frostad joined Steve Darling from Proactive to announce the start of the company's fully funded summer 2026 drill program at the Dorado Project, a 50/50 joint venture with IsoEnergy located in Saskatchewan's Athabasca Basin. The program is designed to build on the success of the Nova Discovery, where winter drilling expanded uranium mineralization along a one-kilometre structural corridor and significantly improved the company's geological understanding of the system. Frostad said the summer campaign will consist of seven drill holes totaling approximately 3,150 metres and will run through July and August. The primary objective is to further expand the Nova Discovery while also testing several high-priority regional targets across the broader Dorado property. The program follows a highly successful nine-hole winter drill campaign, which intersected anomalous radioactivity exceeding 500 counts per second (cps) in every hole drilled. Winter drilling also confirmed a peak downhole gamma reading of 73,100 cps, highlighting the strength of the uranium mineralization encountered. Assay results from the winter program remain pending. In addition to drilling, the company recently completed an airborne MobileMT geophysical survey over the Dorado Project. Results from the survey will be integrated into ongoing geological interpretation and future drill targeting efforts, helping refine exploration priorities across the property. Management believes the combination of strong drill results, advanced geophysical data, and a growing understanding of the mineralized corridor positions Dorado as one of the most promising emerging uranium discoveries in the Athabasca Basin. #proactiveinvestors #purepointuraniumgroup #tsxv #ptu #otcqb #ptuuf #UraniumExploration #NuclearEnergy #IsoEnergy #DoradoProject #UraniumExploration #AthabascaBasin #NovaDiscovery #CriticalMinerals #MiningNews #ExplorationDrilling #UraniumStocks

The Advantage of Rapid Prototyping in Wearable MedTech DevelopmentModern cancer treatments are getting better at targeting specific forms of cancer. However, this improved effectiveness often introduces lethal side effects. Skribe Medical is developing wearable technologies to help oncologists monitor and manage these side effects and ultimately improve cancer survivability.In Episode 45 of the MedTech Speed to Data podcast, Key Tech's Andy Rogers has a conversation with Ryan Neely, Skribe Medical's CEO and co-founder, about the startup's approach to rapid prototyping, clinical trials, and wearable technology.Need to knowCancer treatment can be lethal — The most effective drugs often come with black box warnings of harmful and lethal side effects.600,000 US patients are at risk of cardiotoxicity — Toxic drugs damage the heart, leading to complications like arrhythmia and heart failure.Managing cardiotoxicity can delay cancer treatments — Oncologists must now schedule patients for third-party ECG testing, which takes time and delays treatment.The nitty-grittySkribe Medical is developing a wearable ultrasound sensor that detects cardiotoxicity signals for use in oncology clinics. “We have a patch that can be worn to detect cardiotoxicity and really streamline monitoring of heart health,” Neely says. “Rather than an oncologist sending a patient to get a cardiac ultrasound, which could take weeks, the patch can just be placed above the heart for about five minutes. We record a bunch of different signals, pass them through an AI model, and then we can give them either a thumbs up or a thumbs down.”Neely goes on to explain how the in-clinic wearable approach delivers benefits beyond better patient outcomes. “The first device that we're building is intended to be used in the clinic by a nurse or a medical assistant. By the time the doctor is there, you've got your answer.”Designing a wearable device rather than an implant created several advantages for Skribe Medical during its early development. “In a regulated industry like medical devices,” Neely explains, “it's like a little bit of a chicken and egg where people say, ‘we'd like to see some clinical validation' and you're thinking, ‘Well, I don't have a million dollars to fund that.' In a non-invasive device, any opportunity that you can have to test, even if it's this big, bulky thing, you can get some data.”Skribe Medical's technology can extend to other aspects of oncology, including peripartum cardiomyopathy, a rare form of heart failure arising towards the end of a pregnancy. Long-term, Neely envisions building the longitudinal training data needed for predictive monitoring. “What we'd like to do is be able to say, ‘two weeks from now there might be an issue' so you can do something today that prevents any drop [in injection fraction] at all.”Data that made the difference:Skribe Medical's three founders built first prototype at home. They used their home electronics and 3D printing labs to rapidly prototype the first functional sensors.Rapid wearable development delivered data quickly, first by testing themselves and then through clinical testing.Skribe Medical conducted the first clinical tests at an ECG lab where, with consent, the wearable collected patient data for comparison with the patient's ECG results.Having clinical data so early in the process encouraged investors. Last year's pre-seed round raised $1.6 million from angels and VCs to support the next phase of device development and trials.Listen to Andy's conversation with Neely to hear more about Skribe Medical's journey, development process, and the advantages of wearable medical technology.

Erik Wetterling, Founder and Editor of The Hedgeless Horseman website, joins us to review the value proposition that has his attention from recent corporate news and strategies from 3 silver, copper, and gold explorers that have recently press-released significant company milestones.   The companies we discussed in the interview are:   * Silver Bow Mining Corp. (NYSE American: SBMT) – On May 4, 2026 the Company announced that surface drilling has commenced at the Company's Rainbow Block Project in the Butte Mining District of Montana, marking the launch of its 2026 exploration program.   The 2026 program is designed to advance the Company's understanding of mineralization across the Rainbow Block and to support ongoing evaluation of priority silver, gold, zinc, and lead targets. The surface drill program is expected to include approximately 25,000 feet of drilling on Company private lands and test areas adjacent to the Company's previously announced Inferred Mineral Resource Estimate of approximately 170 million silver equivalent ounces at 14.8 oz/ton (or 4.28 oz/ton Ag, 0.05 oz/ton Au, 1.25% Pb, and 4.59% Zn).   * Barksdale Resources Corp. (TSXV: BRO) (OTCQB: BRKCF) (FSE: 2NZ) – On May 4, 2026 the Company announced assay results from the first four holes of the 2026 reverse circulation drill program on its flagship Sunnyside Project located in Arizona, USA. Assay results show several broad areas of shallow, high-grade copper-zinc-silver mineralization hosted within the Sunnyside Monzonite Porphyry.   Highlights include:   0.45% Cu over 392.19m from 3.05m to 396.24m in hole SUN26-002R including: 0.90% Cu over 60.96m from 173.74m to 234.70m 0.93% Cu over 60.96m from 265.18m to 326.14m Hole ended in mineralization 0.29% Cu over 454.15m from 3.05m to 457.20m in hole SUN26-001R including: 0.95% Cu over 39.63m from 248.41m to 288.04m Hole ended in mineralization   * Headwater Gold Inc. (CSE: HWG) (OTCQX: HWAUF) - On April 28, 2026, the Company announced results from the recent core drilling program at its TJ Project in Elko County, Nevada. The program was fully funded by OceanaGold Corporation (TSX: OGC, NYSE: OGC) pursuant to the earn-in agreement announced October 15, 2025.   Highlights: Highest gold grades to date: Core drilling returned grades up to 5.61 grams per tonne gold (“g/t Au”), confirming the presence of a high-grade epithermal vein system below the surface sinter.  Large, dynamic hydrothermal system confirmed: Drilling intersected 100 m thick hydrothermal breccia intervals, syn-mineral intrusions and multiple phases of epithermal veining across more than 500 metres of strike length. System open and expanding: Drilling has tested only a small portion of the system, but mineralization remains open at depth and along strike. The Company recently expanded the TJ land position by 88% (to 1,990 hectares) to cover the prospective northern continuation of the TJ graben.       * In full disclosure, some companies mentioned by Erik in this interview, are positions held in his personal portfolio, and also may be site sponsors of The Hedgeless Horseman website at the time of this recording.   Click here to follow Erik's analysis over at The Hedgeless Horseman website   For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned, and companies profiled may be sponsors of the KE Report.

In the final episode of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss the study results and their implications for improving clinical practice.  Read more about this abstract on the AAN website. 

In part two of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss how this technology was developed and how it has evolved.  Read more about this abstract on the AAN website. 

In this Company Update, I am joined by Mike Burke, Director and VP of Corporate Development at Sitka Gold (TSX.V: SIG | OTCQB: SITKF | FRA: 1RF). Mike provides a comprehensive breakdown of the newly analyzed tungsten data and how it integrates into the existing gold resource at the Rhosgobel gold deposit. We discuss the geological significance of these results, the potential for tungsten as a high-value by-product, and what this means for the project's future economics. Key Discussion Points: Tungsten Resource Potential: Mike discusses the re-sampling of 33 drill holes and the confirmation of tungsten mineralization over an 850-meter strike length. Metallurgical Synergy: An overview of how tungsten (in the form of scheelite) can be recovered using gravity and flotation - the same methods planned for the project's gold recovery. Critical Mineral Strategic Value: Insights into tungsten's status as a critical mineral and how its current high market price could impact the overall value of the RC Gold Project. 2026 Exploration Outlook: A look at the ongoing 60,000-meter drill program and the upcoming milestones.   If you have any follow up questions for the team at Sitka Gold please email me at Fleck@kereport.com.  Click here visit the Sitka Gold website to learn more about the Company - https://sitkagoldcorp.com/   --------------- For more market commentary & interview summaries, subscribe to our Substacks:  The KE Report: https://kereport.substack.com/  Shad's resource market commentary: https://excelsiorprosperity.substack.com/   Investment Disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security or investment product. Investing in equities, commodities, really everything involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

Purepoint Uranium Group CEO Chris Frostad joined Steve Darling from Proactive to report strong results from the company's winter 2026 drill program at the Nova Discovery, part of the Dorado Joint Venture Project in Saskatchewan's Athabasca Basin. Purepoint, operator of the 50/50 joint venture with IsoEnergy, completed 5,210 metres of drilling across nine holes within the Nova Zone. The program successfully extended both uranium mineralization and favourable geology, further strengthening the discovery. Downhole probe readings reached a peak of 73,100 counts per second, building on previously reported assay grades of up to 8.1% U₃O₈ at the Nova Discovery. Assay results from the winter 2026 program are currently pending. Frostad noted that the drilling campaign expanded mineralization at Nova and extended the associated geological contact to approximately one kilometre in strike length. The results have also helped establish a more refined targeting framework to support continued exploration and expansion. Looking ahead, regional drilling at the Dorado Joint Venture Project is expected to resume in late June 2026. In addition, an airborne MobileMT survey is planned for the spring, with interpretation results set to guide summer drill targeting. #proactiveinvestors #purepointuraniumgroup #tsxv #ptu #otcqb #ptuuf #UraniumExploration #DoradoProject #NorthernSaskatchewan #NovaDiscovery #IsoEnergy #HighGradeUranium #MiningExploration #DrillingResults #Geophysics #ResourceExpansion #NuclearEnergy #CriticalMinerals #ExplorationUpdate #SaskatchewanMining

In the first part of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss the background and evolving terminology around circulating tumor DNA, cell‑free DNA and CSF‑based testing in neurology.  Read more about this abstract on the AAN website. 

Interview with Jeffrey R. Wilson, President & CEO of Precipitate Gold Corp.Our previous interview: https://www.cruxinvestor.com/posts/precipitate-gold-corp-tsxvprg-funding-secured-as-barrick-adjacent-drilling-starts-9454Recording date: 2nd April 2026Precipitate Gold Corp. (TSXV:PRG) is approaching what may be the most consequential period in its history. The Vancouver-based junior explorer holds three gold-copper projects in the Dominican Republic (all 100% owned) and is now executing on the phase of exploration that carries the highest potential for value creation: active discovery drilling.The company's two flagship assets are strategically located. Juan de Herrera shares a border with Goldquest Mining's Romero deposit, a 3.5 million gold-equivalent ounce resource advancing through feasibility and environmental review. Pueblo Grande surrounds Barrick Gold's Pueblo Viejo mine, one of the largest gold-producing operations in Latin America. In both cases, the host geology is known, the mineralisation style of high-grade gold and copper is confirmed in adjacent ground, and the question now is whether Precipitate's targets contain comparable mineralisation at economic grades.That question will be answered by the drill bit over the course of 2026. The company has planned up to 10,000 metres of drilling across multiple zones on both projects, with Pueblo Grande already in an active program and Juan de Herrera in final preparation for mobilisation. At Juan de Herrera, years of methodical exploration work of approximately 18,000 soil samples and subsequent induced polarisation geophysical surveys have identified multiple zones where elevated gold and copper at surface coincide with strong chargeability anomalies at depth. This is precisely the geochemical and geophysical signature that defines the Romero and Cachimbo mineralised zones on neighbouring Goldquest ground, lending the targeting approach a credible, data-driven foundation.The financial position supports the program without immediate dilution risk. A $6.5 million financing completed in January 2026, led by Dominican institutional investors, brought the total working capital to approximately $9 million. Those same investors hold approximately $5 million in in-the-money warrants, providing an additional funding lever should the drill program warrant expansion. The participation of locally connected Dominican capital is significant not only financially but as a signal: investors with direct knowledge of the political and regulatory environment have chosen to back the company at scale.The jurisdictional backdrop has improved meaningfully. The Dominican government has moved toward a more pro-mining stance, with faster permitting and demonstrated willingness to support projects through the development pipeline. Goldquest's advancement of Romero toward feasibility is providing the sector's first real proof of concept that the country can host a project from discovery through to production-ready status.From a valuation standpoint, Precipitate has historically traded in close ratio to Goldquest, despite Goldquest holding the established resource. That relationship has diverged over the past two years as Goldquest re-rated on the back of jurisdictional improvements and project advancement. Management believes the gap represents an opportunity, with exploration success at Juan de Herrera or Pueblo Grande the most direct mechanism to close it.Assay results from both projects, expected progressively across 2026, will define the investment outcome. For investors with the risk tolerance appropriate to early-stage exploration, the current setup in terms of geological, financial, and jurisdictional is as well-structured as Precipitate has ever presented.View Precipitate Gold's company profile: https://www.cruxinvestor.com/companies/precipitate-gold-corpSign up for Crux Investor: https://cruxinvestor.com

Interview with Steven Sirbovan, President & CEO of ICG Silver & GoldRecording date: 1st April 2026ICG Silver and Gold Corp. is a newly listed exploration company that began trading on the CSE on March 31, 2026, after spinning out from American Pacific Mining. The company holds a single flagship asset, the Tuscarora District, a 10,000-acre contiguous land package in northeastern Nevada positioned at the intersection of the Independence and Carlin Trends. For investors evaluating the junior exploration space, ICG presents a clearly defined near-term catalyst, a funded treasury, and a geological thesis that differentiates it from prior operators at the same project.The Tuscarora District is not a greenfield exploration play. Historical operators Novo Resources and American Pacific Mining conducted 25,000 metres of drilling, collected 5,000 samples, and completed 130 line-kilometres of geophysics across the property. Those programs generated high-grade results, including an intersection of just over 4 metres grading 127 g/t gold at the South Navajo target. Despite this work, the project was consistently treated as a gold-only system. ICG's management believes that interpretation left a significant dimension of the project unexplored: a spatially overlapping, silver-dominant epithermal system, supported by surface rock samples returning up to approximately 38,000 g/t silver at certain targets and near-surface geophysical anomalies.The former Dexter open-pit mine, located just off the property boundary on trend with the South Navajo and Modoc targets, produced approximately 50,000 ounces of gold and 250,000 ounces of silver in the early 1990s and serves as a direct analogue for the style of mineralisation management is targeting.The company enters the market with approximately C$6.2 million in the treasury and a Phase 1 RC drill program of 3,000 to 6,000 metres scheduled to commence in June 2026. RC costs in the region are currently estimated at approximately US$250 per metre, providing ICG with sufficient capital to complete the program without near-term financing pressure. Assay results are expected in August 2026, giving investors a defined newsflow window within the current calendar year.The Phase 1 program targets two categories of drill holes. The first group focuses on South Navajo and Modoc to build toward an eventual mineral resource. The second and more exploration-oriented group targets East Pediment, Grand Prize, King's Vein, and North Navajo areas which are identified through sampling and geophysics but not yet systematically drilled. Hole depths are planned at 200 to 300 metres, consistent with the shallow, open-pittable mineralisation model the company is evaluating.The management team brings relevant capital markets and technical depth. CEO Steven Sirbovan has 13 years of capital markets experience including work at Waterton Global Resource Management with a Nevada focus. The board includes Jeff Swinoga, formerly of Barrick Gold, and Gary Baschuk, who spent significant time at Barrick's Goldstrike operation in Nevada. VP of Exploration Korbon McCall provides direct technical continuity with the project through his prior work with American Pacific.For investors, the near-term thesis is straightforward: a funded drill program, an August 2026 assay window, and a geological interpretation that has not previously been tested at district scale. The key risk, as with any early-stage exploration company, is that drilling results may not confirm the dual-system thesis. Investors should size positions accordingly and monitor Phase 1 results as the primary near-term value inflection point.Learn more: https://cruxinvestor.comSign up for Crux Investor: https://cruxinvestor.com

Entrevista Completa ==> https://youtu.be/xMsx2sgFro8Neste programa especial, o podcast da mineração recebe Eduardo Rodrigues Coordenador Técnico e Comercial da Corona Cadinhos e Refratários, que é uma empresa focada em alta performance e durabilidade. Maximizamos os seus resultados com eficiência, segurança e confiabilidade.Este é o segundo episódio de uma série imperdível que trará insights valiosos sobre as tecnologias de ponta da empresa! Para abrir com chave de ouro, nosso tema é: Cadinho no Processo de Refino. Em um bate-papo exclusivo, entrevistei o representante da Corona Cadinhos, que compartilhou os bastidores e os detalhes essenciais dessa etapa crucial. Descubra como transformar o conhecimento técnico dos cadinhos em mais eficiência, segurança e máxima qualidade no seu processo de refino.Entre em contato com a Corona Cadinhos e Refratários:Instagram: @coronacadinhosWhatsApp: 11 963343339https://coronacadinhos/ - https://coronacadinhos.com.br/contato/Assista ao vídeo e descubra como a Corona Cadinhos e Refratários transforma a fundição em uma operação segura: tecnologia de alta performance para quem não tem tempo a perder.

Diagnostic laboratories are a key part of the veterinary care team, but one most…

Diagnostic laboratories are a key part of the veterinary care team, but one most people don't commonly interact with. Dr. Michael Dark, clinical associate professor and director of UF's veterinary...

Interview with Tara Christie, President & CEO of Banyan Gold Corp.Our previous interview: https://www.cruxinvestor.com/posts/banyan-gold-tsxvbyn-76moz-gold-project-advances-toward-2026-pea-8866Recording date: 1st March 2026Banyan Gold Corp. (TSXV:BYN) enters 2026 as one of the more substantive junior gold development stories in Canada's Yukon Territory. With a 7.7-million-ounce gold resource at its AurMac project, a fully funded 40,000-metre drill program underway, and a maiden Preliminary Economic Assessment scheduled for the second half of the year, the company has a clear and near-term catalyst pipeline.The 2025 drill program of approximately 43,000 metres targeted two high-grade zones—Airstrip and Powerline—which are expected to anchor the starter pit economics in the upcoming PEA. Intercepts of 16 metres at 9 g/t and 40 metres at 4 g/t at Airstrip, and multiple 2–3 metre intervals at 16 g/t at Powerline, represent above-average grades relative to the broader deposit. Assay results from the full 2025 campaign remain pending, with a resource update to follow. Step-out drilling has extended the deposit's surface expression by approximately one kilometre in both directions along Airstrip, reinforcing management's view that AurMac is a substantially larger system than legacy models indicated.A separate high-grade silver discovery—18 drill hits across six shallow veins, with grades exceeding 13,000 g/t at depths as shallow as 65 metres—adds a layer of optionality not yet captured in any economic study. The most significant external data point for valuing AurMac is Franco-Nevada's February 2026 acquisition of the project royalty for $52.2 million. The royalty carries a buydown provision reducing it to 1% for $10 million—meaning Franco-Nevada effectively paid approximately $42 million for a 1% net smelter royalty. At Banyan's current market capitalisation, this implies the equity market is ascribing a fraction of the value to the full project that a leading royalty company paid for just one percent of it. That gap is the central valuation argument for the stock.Despite a share price increase of approximately 350% in 2025, Banyan trades at under US$50 per ounce of resource. Yukon development peers trade at US$60 to US$300 per ounce. Christie noted that comparable companies were achieving the US$50/oz valuation at US$1,800 gold—implying the current per-ounce value has not kept pace with the commodity. Three investor misconceptions resolved in October 2025—heap leach versus mill, legacy shareholding overhang, and partial property ownership—had suppressed the stock relative to peers and have now been corrected.Execution risk is reduced by full funding secured in October 2025, an early season start with five drills operating by mid-March, and contracts with senior field personnel signed ahead of competitors. The company is not seeking additional capital and is focused on delivering value from existing resources.The PEA in H2 2026 is the defining event. It will establish the first public economic framework for AurMac and provide the foundation for any subsequent corporate transaction, partnership, or development financing discussion. For investors positioned ahead of that catalyst, the combination of resource scale, jurisdictional quality, external royalty validation, and a measurable per-ounce discount to peers represents a specific and trackable investment case.View Banyan Gold's company profile: https://www.cruxinvestor.com/companies/banyan-gold-incSign up for Crux Investor: https://cruxinvestor.com

C3 Metals CEO Dan Symons joined Steve Darling from Proactive to report new drill results from the company's Khaleesi copper project in southern Peru, highlighting encouraging early-stage exploration success. C3 Metals has completed 12 diamond drill holes totaling 6,300 metres, with copper mineralization observed in all completed holes across a footprint measuring approximately 1,000 metres by 500 metres. Step-out drilling has extended up to 300 metres, marking the first-ever drill testing at the greenfield Khaleesi project. Assay results from the first two holes were previously released. The company has now received assays from an additional four holes, with multiple intercepts of broad skarn- and diorite-hosted copper mineralization. Highlights include hole KHZ5825-001: 101.1 metres grading 0.30% copper, 0.045 g/t gold, 0.84 g/t silver, and 48 ppm molybdenum (0.37% CuEq) from 23.4 metres downhole and KHZ5950-001: 243.7 metres grading 0.24% copper, 0.020 g/t gold, 0.87 g/t silver, and 41 ppm molybdenum (0.29% CuEq) from approximately 200 metres vertical depth. Symons said results from the first six assayed holes, combined with visual observations from the remaining six holes, suggest potential for higher-grade mineralization in the western and southwestern areas of the project. Mineralization in the eastern and northeastern portions appears more distal from what management describes as the system's “heat engine.” With additional drilling, the company aims to better define the geometry of the mineral system and vector toward higher-grade zones, potentially associated with a porphyry source. Following completion of the initial 6,300-metre Phase 1 program, C3 Metals has launched an aggressive 2026 drill campaign. The company plans to drill an additional 15,000 metres this year, targeting a total of 21,300 metres by year-end. Management is continuously refining its geological model to better target skarn-hosted mineralization and evaluate the potential for an underlying porphyry system. #proactiveinvestors #c3metalsinc #tsxv #cccm #otcqb #cuauf #KhaleesiProject #KhaleesiProject #CopperExploration #PeruMining #SkarnMineralization #PorphyryTarget #DiamondDrilling #DrillResults #CopperGold #Molybdenum #ResourceExpansion #GreenfieldProject #MiningExploration #CopperDiscovery #BaseMetals #Phase1Drilling #2026DrillProgram #GeologicalModel #AndeanMining #CuEq

Design for Security from the Start: Making Medical Device Cybersecurity More ResilientMedTech innovation is revolutionizing healthcare but is also introducing new cyberattack vectors that can put manufacturers, hospitals, and patients at risk.In Episode 44 of the MedTech Speed to Data Podcast, Key Tech VP of Business Development Andy Rogers and Senior Computer Engineer Jamie Kendall discuss the FDA's latest cybersecurity guidance.Need to knowSmart, connected devices have greater risks — Medical devices are emerging vectors for bad actors targeting the healthcare industry.FDA's 2025 cybersecurity guidance update — The agency recommends risk-based development frameworks to make device cybersecurity more resilient.Clarifying “cyber devices” — The FDA's guidance applies to any medical device that runs software and could connect to the Internet.The nitty-gritty“Cybersecurity was always baked into our process,” Jaime explains. More specifically, Key Tech has adapted the TIR57 risk-based standard for managing medical device security to the new rules. “[The FDA's] 2023 guidance really laid the groundwork for our latest process. We've tweaked it slightly with the [latest update]. There are more explicit documentation requirements around vulnerability monitoring and more details on the software bill of materials (SBOMs).”Jamie goes on to describe how Key Tech's cybersecurity risk management plan informs product development. The security team starts by developing a threat model based on evaluations of data flows, data storage, and the cybersecurity activities protecting that data. “One of the first things that we always do is a threat model. This is a visual model of the system to show the elements of the device, where data is flowing, and where your trust boundaries are. This is a one-page, digestible visual that everyone can look at, assess, and go ‘yep, that makes sense' and then build your initial architecture and risk assessment based on that.”The security team documents the resulting security architectures using the FDA's recommended views:Global System View: Describes how software integrates with hardware and networks and the associated cybersecurity mitigations.Multi-Patient Harm View: Identifies mitigations for vulnerabilities or failures that could compromise multiple devices and harm multiple patients.Updateability/Patchability View: Summarizes the end-to-end process for distributing software updates and patches, especially if manufacturers do not control the entire path.Security Use Case View: Documents scenarios in which vulnerabilities can compromise the device's safety or effectiveness.“To give a sense of scale,” Jamie says, “this isn't one or two documents. It's a pretty large effort, and it's one of those things that you want to start early in your development process.”Data that made the difference:Throughout his conversation with Andy, Jamie shares some of the lessons Key Tech has learned about designing secure medical devices, including:Design for security from the beginning. Late changes are expensive, especially once in pre-production or after your FDA submission.Avoid cyber rabbit holes. Rather than addressing every possible threat, use data and risk to prioritize the real threats.Don't roll your own cybersecurity. Stick to standard practices, or you risk introducing unknown, novel vulnerabilities.Fully document your SBOMs. Standard libraries introduce layers of dependencies that you must understand. That's the only way to control your exposure to new vulnerabilities.Design devices that are truly safe. Cybersecurity risks are real. Don't treat compliance as a check box.Watch the whole conversation in the video below to learn more about designing for cybersecurity, the importance of third-party penetration testing, and more.

Roger Rosmus, Founder, CEO, & Director of Goliath Resources (TSX.V: GOT) (OTCQB: GOTRF), joins us live from the AME Roundup to highlight the positive investor sentiment after attending 3 back-to-back Vancouver resource conferences.  Additionally, we dig into recent news released on the final 70 gold-only drill hole assays returned from last year's program, the pending assays for 110 multi-element results on all the 2025 drill holes, along with a number of corporate initiatives around not doing a share consolidation, on buying back the NSR from 3% down to 2%, and on fast-tracking its ownership in the Golddigger Property located in the Golden Triangle, B.C. that hosts the high-grade Surebet gold discovery from 49% to 100%.   Drill hole GD-25-319 intersected 19.13 g/t Au over 6.10 meters, including 22.86 g/t Au over 5.10 meters, including 29.09 g/t Au over 4.00 meters in quartz-sulphide veins, part of the Golden Gate Zone Assays are still pending for 110 drill holes from 2025 for multi-element gold equivalent (AuEq) results. These results will be released in the near future once all assays have been received, compiled and interpreted. 100% of the drill holes completed to date, have all intersected gold mineralization clearly demonstrating the remarkable continuity, grades, and widths in 5 Main Gold-Rich Zones comprising 46 mineralized lodes that remain open for expansion. Of the holes drilled during the 2025 campaign, 83 out of 110 holes (or 76%) contained visible gold to the naked eye (VG-NE). The fully funded 2026 drill program will be mainly focused on expanding the 5 Main Mineralized Zones. Data compilation and interpretation is underway which will be used to vector in on the indicated Motherlode causative intrusive source to this extensive high grade gold system with widespread VG-NE.     As part of the transaction to J2 Syndicate Holdings Ltd. to acquire 100% ownership in the Golddigger Property, that Goliath is now set to publish a Maiden Resource Estimate (MRE) on the Golddigger Property before June, 1 2030 and on every 3 year anniversary of June 1,2030 thereafter vs. the prior requirement, in the original agreement, to publish the MRE by June 1, 2027.    Roger outlines the Company's rationale that it makes far more sense to keep expanding the mineralization with aggressive exploration programs, versus trying to pin down the MRE at this stage. He provides both positive examples of companies that have taken this route, versus the negative examples of companies that rushed to put out a MRE, only to fence themselves in with regards to valuations and market perceptions.   Wrapping up, we reviewed that in December cornerstone investors Rob McEwen and Crescat Capital increased their stakes in the company, as well as discussing the optionality that Goliath has with regards to their equity holdings of McEwen Inc shares which have essentially gone up about 3X since acquiring them.  In addition to future conversion of warrants from Rob McEwen, the (MUX) shares provide the option for more capital inflows into the company treasury to fund more exploration.   If you have any questions for Roger about Goliath Resources, then please email us at Fleck@kereport.com or Shad@kereport.com.     In full disclosure, Shad is a shareholder of Goliath Resources at the time of this recording and may choose to buy or sell shares at any time.   Click here to follow the latest news from Goliath Resources   For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

rWotD Episode 3152: Thomas Pitt of Boconnoc Welcome to random Wiki of the Day, your journey through Wikipedia's vast and varied content, one random article at a time.The random article for Saturday, 20 December 2025, is Thomas Pitt of Boconnoc.Thomas Pitt (c. 1705 – 17 July 1761), of Boconnoc, Cornwall, was a British landowner and politician who sat in the House of Commons between 1727 and 1761. He was Lord Warden of the Stannaries from 1742 to 1751. Pitt was the grandson and namesake of the better known Thomas Pitt and the son of Robert Pitt, MP, of Boconnoc, near Lostwithiel in Cornwall. His mother was Harriet Villiers, daughter of Edward FitzGerald-Villiers and the Irish heiress Katherine FitzGerald. Thomas Pitt was the elder brother of William Pitt the Elder. He succeeded his father in 1727 to his estates, including Boconnoc.As head of the family, Pitt inherited both his grandfather's immense fortune and his parliamentary boroughs - he had the complete power to nominate both MPs at Old Sarum and one of the two at Okehampton, as well as considerable influence in at least two Cornish boroughs, Camelford and Grampound. He had himself elected Member of Parliament for Okehampton in 1727, the first election after he came of age, and represented the borough until 1754; but on a number of occasions he was also elected for Old Sarum, which meant that when he chose to sit for Okehampton the Old Sarum seat was free to offer at a by-election to somebody else who had failed to get into Parliament.Pitt was Assay master of the Stannaries from March 1738 to February 1742 and Lord Warden of the Stannaries from February 1742 to March 1751, when the Cornish Stannary Parliament met for the last time.Pitt was ambitious for political influence and, attaching himself to the retinue of Frederick, Prince of Wales, managed the general elections of 1741 and 1747 in Cornwall in the Prince's interests; but this involved massive expenditure - especially at the notoriously-corrupt Grampound, where he spent huge sums both on bribing the voters and on lawsuits attempting to deprive the most rapacious of their votes. By 1751 he had bankrupted himself, and the death that year of the Prince of Wales destroyed his hopes of securing influence or patronage for his efforts. He mortgaged his boroughs to the Treasury, allowing the government to name two MPs at Old Sarum and one at Okehampton in return for a pension of £1000 a year. After sitting briefly for Old Sarum in the 1754 Parliament, he resigned his seat and fled the country.Returning to England in 1761, however, Pitt persuaded the government to allow him to be once more elected for Old Sarum - a temporary measure, he promised, to prevent his being arrested for debt until he was able satisfy his creditors. (MPs were immune from civil arrest.) He promised to relinquish the seat at the earliest possible moment and allow the government to name his replacement in accordance with the original arrangement; but he died a few months later, still MP for Old Sarum.Pitt had married, c.1731, Christian, the daughter of Sir Thomas Lyttelton, 4th Baronet, M. P., of Hagley, Worcestershire and the sister of Lord Lyttelton. They had two sons and two daughters. He afterwards married, in 1761, Maria, the daughter of General Murray.Pitt died on 17 July 1761. His only surviving son was the first Baron Camelford, who repudiated his father's arrangement for Old Sarum, and chose himself as MP when he inherited the borough.This recording reflects the Wikipedia text as of 00:17 UTC on Saturday, 20 December 2025.For the full current version of the article, see Thomas Pitt of Boconnoc on Wikipedia.This podcast uses content from Wikipedia under the Creative Commons Attribution-ShareAlike License.Visit our archives at wikioftheday.com and subscribe to stay updated on new episodes.Follow us on Bluesky at @wikioftheday.com.Also check out Curmudgeon's Corner, a current events podcast.Until next time, I'm standard Salli.

Interview with Gordon Neal, President, Domestic Metals Recording date: 9th December 2025Domestic Metals has acquired a promising Montana copper porphyry project from Rio Tinto through an earn-in agreement that highlights the property's significant potential. The company can earn 60% ownership by spending $3.15 million USD on exploration work, with Rio Tinto retaining 40% plus an unusual 20% clawback provision—a protective measure that underscores the major miner's conviction in the project's long-term value.The Smart Creek-Sunrise property occupies compelling geological ground, located 50 kilometers northwest of the historic Butte mine, which has produced 22 billion pounds of copper over a century. The project sits within the same Helena formation geology, with company geologists noting that rocks match Butte's characteristics in age and composition. Rio Tinto drilled 26 of 40 total holes on the property, with results improving progressively from southeast to northwest. The best intercept to date shows 109 meters at 0.75% copper, including 80 meters at 0.97% copper, suggesting drilling was advancing toward rather than away from the porphyry center.President Gordon Neal brings proven credentials, having built MAG Silver from $50 million to $2.5 billion market capitalization and New Pacific Metals from $100 million to $1.5 billion. His track record in capital markets and project development provides credibility to the company's exploration strategy.The company recently raised $4 million to fund comprehensive IP and magnetotelluric geophysical surveys in January-February 2026, followed by 3,000+ meters of drilling starting February-March. Assay results are expected April-May 2026. A critical advantage is Montana's streamlined permitting environment, with drill permits obtained in four months versus 5-7 years in Arizona. The Forest Service recently extended 36 expired drill permits using existing paperwork—unprecedented flexibility that enables rapid, capital-efficient advancement of what could become a significant domestic copper discovery.Sign up for Crux Investor: https://cruxinvestor.com

HSBC Innovations is the global bank's financing arm for American and European startups, especially in the healthcare and life sciences industries. The bank's semi-annual Venture Healthcare Reports document trends in the investment market.Key Tech's Andy Rogers welcomes the report's author, HSBC Innovation Managing Director Jon Norris in Episode 43 of the MedTech Speed to Data podcast.Need to know·       Four core market segments — HSBC Innovation's Venture Healthcare Reports cover investments and exits in Biopharma, Dx/Tools, Med Device, and Healthtech.·       Sourcing investment data — Norris enriches Pitchbook data with additional structure and analyses, making the report more relevant to these market segments.·       Sourcing exit data — Norris supplements media and industry publications with market research and conversations with industry leaders.·       An investment data tapestry — The reports provide “an honest picture of what's going on in the market” so investors and innovators alike “can make targeted smart decisions.”The nitty-grittyAndy and Norris discuss the investment market's recent history before exploring drivers of today's investment headwinds.“2021 was a record-setting year,” Norris recalls. “Every record that could be set for deals and dollars was set across all the sectors.” Things changed in 2022 as new BioTech IPOs struggled, prompting investment reprioritizations.“VCs had done all these… frothy valuations,” Norris says. “They had to go back and look at their own portfolios and say, does this company have enough capital? How do you want to put money to work?”Investments rebounded in 2024, but not the number of deals. Investors poured money into their existing portfolios to boost their exit chances, resulting in today's nine-figure megadeals.“Basically, they're smooshing two rounds together and extending the investors coming in to support that round,” Norris says.Headwinds stiffened in 2025 as tariffs, a more litigious competitive space, and other factors amplified business uncertainty.Norris attributes this progression to the psychology of venture capital. “When you think about what makes these folks tick,” Norris explains, “they want to continue to raise new venture funds because they get paid management fees. But in order to raise their new venture funds, they have to show their investors that they've actually gotten returns.”That means reaching an acquisition or IPO. “They're very focused on getting to exit right now. That's why they're so focused on their existing portfolio. And because of that, they haven't been doing as many new investments.”New investments still happen, of course, but the criteria have changed. “While the dollars are actually up in some of these sectors, especially Med Device,” Norris says, “you're seeing that being put to work on later-stage deals because they'd rather get a shorter time to exit.”Data that made the difference:Norris' insights from the HSBC Venture Healthcare Report let him advise startups fighting today's investment headwinds.Adopt a megaround mentality. “Series B has been extremely difficult,” Norris says. “[Raising] sub two million, that's one thing. But if you're looking to raise five million, it's almost better to raise twelve.”Find investors outside the mainstream. “Traditional venture investors don't want to write small checks.” Norris sees angel groups, innovation centers, and other small investors funding these early rounds.Explore acquisition exits, but be careful. “On the device side, most of the corporates have been pretty darn active,” Norris says. However, some litigate to block emerging competition, especially in the Dx/Tools sector. Norris' recommends researching potential acquirers before taking meetings.Download the HSBC Venture Healthcare Report for Norris' complete analysis, and watch the video below for insights into the Medical Device and Dx/Tools sectors, AI's role in MedTech, and more.

Nuclear Proliferation Concerns Regarding Small Modular Reactors and Weapons Testing. Henry Sokolski raises proliferation concerns about Small Modular Reactors (SMRs) using High-Assay Low-Enriched Uranium (HALEU) fuel (20% enriched). Declassified cables from 1954 and 1977 suggested that uranium above 10% requires special concern, demanding a review before SMRs are exported. Sokolski also clarifies that US maintenance of its nuclear arsenal relies on non-critical tests and simulations, not full-yield explosions, though adversaries may be conducting critical tests.

Nuclear Proliferation Concerns Regarding Small Modular Reactors and Weapons Testing. Henry Sokolski raises proliferation concerns about Small Modular Reactors (SMRs) using High-Assay Low-Enriched Uranium (HALEU) fuel (20% enriched). Declassified cables from 1954 and 1977 suggested that uranium above 10% requires special concern, demanding a review before SMRs are exported. Sokolski also clarifies that US maintenance of its nuclear arsenal relies on non-critical tests and simulations, not full-yield explosions, though adversaries may be conducting critical tests.

In-utero procedures can yield better long-term outcomes for the baby. However, fetal surgery relies on instruments developed for other disciplines. An early-stage startup in Maryland is developing in-utero instruments to improve outcomes for both fetus and mother.Fetal Therapy Technologies CEO Selena Shirkin joins Key Tech's Andy Rogers for Episode 42 of the MedTech Speed to Data podcast to discuss startup innovation in fetal surgery.Need to knowFetal surgeries carry risks — In addition to uterine damage complicating future pregnancies, 40% of surgeries have a risk of preterm birth.Few specialized tools are used — In the field's forty-year history, the FDA has only approved the Karl Storz Fetoscope for use in fetal surgeries.Off-label device use is widespread — Equipment borrowed from adjacent fields like laparoscopy and neurosurgery weren't indicated for use in the uterus.The nitty-grittyShirkin and Chief Technology Officer Eric McAlexander founded Fetal Therapy Technologies as students in Johns Hopkins University's biomedical engineering graduate program. While shadowing surgeons, they saw how off-label instruments complicated procedures.“I watched a surgeon using a grasper and suture,” Shirkin recalled. “The suture was falling out of the grasper because they didn't fit. It took time in the surgery to make sure that didn't occur.”Observations like these led the team to wonder why the field lacked optimized tools. “As biomedical engineers,” Shirkin says, “we asked ourselves what if we created those purpose-built instruments that actually make these procedures safer?”They quickly ran into the commercial limits of a market as small as fetal surgery. With only one device FDA-approved for in-uterine procedures, surgeons have no choice but to use devices off-label. So Fetal Therapy Technologies is flipping the script by leveraging the broader applications of an instrument designed for fetal surgeries.“In a way, our company solves two problems at once,” Shirkin says. “A company that creates a fetal innovation [that] also raises a much broader market of general microsurgery.”Their first product is a uterine port. “Similar to laparoscopic surgeries,” Shirkin explains, “that involves inserting a port through the abdomen into the uterus. [The new] port is designed to leverage the elastic properties of the uterine environment to make entry safer than the current clinical standard.”For broader commercialization, they aim to demonstrate equivalence to predicate devices and qualify as a 510(k) Class II device following benchtop and animal studies. Approval for fetal surgeries is a longer journey, but the company can build on its data before entering human trials.Data that made the difference:Shirkin offered insights for other students considering an entrepreneurial future in MedTech.Leverage university resources. “We work incredibly closely with the Johns Hopkins Center for Fetal Therapy,” Shirkin says. We've also gotten opportunities from Johns Hopkins Technology Ventures.”Build a network of advisors. “We are supported by a very broad variety of clinical, technical, and business mentors across the Johns Hopkins ecosystem and beyond.”Tap into local funding sources. “There's a lot of collegiate business plan competitions that we've been very successful [raising] non-dilutive funds that way. There are also state-level grants. We just received a Baltimore Innovation Initiative grant.”

AABP executive Director Dr. Fred Gingrich reviews a paper published in The Bovine Practitioner with two of the authors. Joining today are Dr. Greg Habing, professor in the Department of Preventive Medicine at The Ohio State University College of Veterinary Medicine, and Dr. Emily Nogay, clinical assistant professor at The Ohio State University Large Animal Ambulatory Services.  Salmonella Dublin is a host-adapted and zoonotic pathogen affecting many dairy farms. It can be associated with high morbidity and mortality and is often multi-drug resistant which elevates its importance to dairy farmers and veterinarians. Surveillance and diagnostics are an important aspect of managing diseases in our herds. Nogay reviews available diagnostic tests and the advantages and disadvantages of each one. The ELISA test has a sensitivity of 65%, but is used to screen herds for the disease. The objective of this study was to determine if the four U.S. commercially licensed Salmonella vaccines would result in a positive Salmonella Dublin ELISA test result.  We walk through the results of the paper and discuss some of the findings, including the impact of the vaccines on the serum ELISA results and some potential reasons for the ELISA results after vaccination. Habing discusses future opportunities for research on this disease, including the need for better diagnostic tests, including a PCR test to screen herds.  AABP's peer-reviewed journal, The Bovine Practitioner, publishes original research studies, reviews, case series, and case reports intended to provide clinically relevant research to private practicing veterinarians. It is an open access journal and there are no publication fees for submitting authors. Read more about the journal at this link.  The effect of Salmonella vaccination on Salmonella Dublin blood enzyme-linked immunosorbent assay results. Bov Pract. 2025;59(2), 53-60. https://doi.org/10.21423/bpj20259266

Hire world-class accountants and in The Philippines. Visit Outsource Direct to scale your operations with higher flexibility, maximum efficiency and much lower costs.Subscribe to the Business Builders Newsletter for the very best ideas I've discovered on business and personal growth.In Series 10, Episode #94, I interview Sean Mac Fhearraigh, co-founder and Chief Scientific Officer at Assay Genie. Sean shares his journey from academic cancer researcher to successful entrepreneur. We delve into the challenges of transitioning from science to business, raising funds, and growing Assay Genie into a multimillion-euro enterprise. The conversation spans topics like the importance of credibility in the scientific market, the impact of AI on science, and personal sacrifices made along the way.CONNECT WITH CONOR:LinkedInCONNECT WITH SEAN:LinkedInAssay GenieDiscover EO Ireland—part of an international network designed specifically for entrepreneurs. EO Ireland connects business owners for networking, mentorship, and shared learning experiences. Take your business to the next level and join a community of like-minded leaders today at eoireland.org. Empower your entrepreneurial journey!Produced by Jetbooks, Chartered Accountants Ireland.

In this week's episode, we'll learn more about how exogenous CD19 stimulation affects CAR T-cell persistence in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy; new algorithms that incorporate sequential rapid immune-assays, intended to improve diagnosis of heparin-induced thrombocytopenia, and resource-adaptive survival prediction models to help guide management of patients with chronic myelomonocytic leukemia.Featured Articles:Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALLSequential combinations of rapid immunoassays for prompt recognition of heparin-induced thrombocytopeniaBLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC, explain how Mayo Clinic Laboratories' expanded test panel captures rarer as well as more common genetic causes of hereditary pancreatitis. That information is key to managing patients' enhanced risk for pancreatic cancer.Speaker 4: (00:32) Could you both please tell us a little bit about yourself and your background? Speaker 4: (02:23) Could you please give the audience a brief overview of this assay?  Speaker 4: (03:53) Which patients should have this test, and when should it be performed? Speaker 4: (04:49) What alternative testing options are available, and how do these compare to the new, expanded panel that we're going to be offering? Speaker 4: (08:20)How are the results used in patient care?

This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠revival-dash-gold.com⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠equinoxgold.com⁠⁠ Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test detects antihypertensive medications in urine, providing evidence of whether patients are absorbing their medications or whether a new treatment approach might be needed. Speaker 3: (00:33) Could you tell us a little about yourselves and your backgrounds? Speaker 3: (01:41) Dr. Taler, could you provide us with a brief background on resistant hypertension? Speaker 3: (03:43) Can you provide a little bit more background on patients who aren't taking their medications? Speaker 3: (05:11) How do physicians currently assess whether patients are taking their medications? Speaker 3: (07:03) Dr. Lieske, could you tell us how this new assay can be used to help physicians manage their patients with hypertension? Speaker 3: (09:43) Dr. Taler, can you tell us how doctors can use this new testing to manage their patients?

Epinephrine auto-injectors, first developed in the 1970s, are the most common emergency treatments for anaphylaxis, often deadly allergic reactions. The limitations of liquid epinephrine and the device's decades-old technology have kept these life-saving devices out of patients' hands. Austin-based startup Windgap Medical, Inc. plans to break these barriers with a more convenient, shelf-stable alternative.In Episode 41 of the MedTech Speed to Data podcast Key Tech's Andy Rogers and Thomas James sit down with Windgap's co-founder and Chief Business Officer, Brent Buchine, to discuss the data-driven development of the company's life-saving technology.Need to know·       Epinephrine auto-injectors are big business — A $1.3 billion market at Windgap's founding, sales of epinephrine auto-injectors exceeded $3.1 billion in 2024.·       Few eligible patients get these life-saving devices — Only 52% of American food allergy patients ever receive prescriptions, and epinephrine auto-injectors are only available in 32% of the world's 195 countries.·       Traditional auto-injectors are relatively large and inconvenient — Only 55% of patients with prescriptions report having immediate access to their auto-injectors.·       Liquid epinephrine is thermally unstable — Doses lose their effectiveness with prolonged heat exposure, forcing patients to refill their prescriptions more frequently.The nitty-grittyBuchine and his co-founders saw an opportunity to make epinephrine delivery more convenient and accessible. “We developed a freeze-dried version of epinephrine to make it more stable and double, if not triple, the shelf life,” Buchine explains.However, lyophilization introduces an extra step in the treatment process. The dried epinephrine must be rehydrated and mixed in a solution before injection.“If you have a rescue product for emergency use, you have to get it very quickly,” Buchine says. “With modest training, you need to make sure people know how to use the product because their life is at risk if it doesn't work.”Windgap's ANDI® platform is a small, highly portable single-dose auto-injector, Buchine explains. “Simply twisting the cap automatically rehydrates that dose in a couple of seconds — no shaking, no swirling required. It's ready to inject by pressing the device next to the injection site.”Windgap and its pharmaceutical clients are still in the commercialization phase, but the company is already looking at the future of complex injectables.“We see that, fundamentally, formulation pipelines are getting more and more challenging,” Buchine says. “You have multiple injections, you have mixing, you have high viscosity/high volume. The conventional options out there are not as suitable anymore. We're solving those problems specifically because we think there's an opportunity to be best in class in that area.”Data that made the difference:Developing combination products is a multi-stakeholder problem. “It's drug, it's device, it's patient, it's prescriber, it's payer. You've got to think about all of those stakeholders along your development.”Get in front of stakeholders to understand the problem. “We did a lot of surveys and uncovered the opportunity. Patients weren't getting prescriptions filled or weren't even going to the doctor to get prescriptions. It was that segment that we spent a lot of time talking to.”Listen to your customers. “We'll talk to pharmaceutical companies [and ask] what are some of the biggest challenges you're facing in your pipeline? And then you just listen. Over time, you look for that recurring theme. That's what really drove our product strategy.”Use data to convince investors. “There was a vastly underserved market. Our ability to communicate that to investors and help them understand the opportunity of taking [at the time] a $1.3 billion business to something substantially above that.”

Joseph Yao, M.D., explains how Mayo Clinic Laboratories' new quantitative assay (Mayo ID: ADVQU) goes beyond qualitative testing to evaluate transplant patients for adenovirus infection. Adenovirus can cause life-threatening disease in immunocompromised transplant patients, especially children.(01:14)Could you give us a brief overview of this assay? (02:06)Can you explain the differences of the qualitative and quantitative methods and why we made the change to a quantitative adenovirus method? (04:00)When is this test typically ordered for transplant patients? Is it used throughout their treatment? (06:56)Could an immunocompromised person be unknowingly infected? (07:31)Is our quantitative method approved for pediatric patients? (08:00)How are the test results used to treat patients?(10:36)What other infections might providers consider alongside adeovirus?

Hundreds of approved devices use artificial intelligence to help physicians diagnose patients faster and more accurately. Brooke & Associates is a legal and regulatory advisory firm that helps medical device makers get AI-powered devices through FDA pre-market approval.In Episode #40 of the MedTech Speed to Data podcast, Key Tech's Andy Rogers and Lei Zong speak with the firm's managing member, Jason Brooke, about the FDA's latest guidance to medical device developers for integrating AI into their products.Need to knowAI's role in MedTech — AI identifies otherwise undetectable data patterns that humans can apply in clinically meaningful ways.FDA's AI staffing surges — The agency accelerated hiring to develop internal AI applications and support pre-market reviews of new AI-powered devices.Radiological imaging leads the pack — More than half of 900+ FDA-approved AI-based products are in radiological imaging.Other fields are catching up — Cardiology and neurology applications are more recent entrants in AI-powered devices, but their numbers are growing.The nitty-grittyThe FDA published “Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations” in early 2025 to explain how it will address AI's adaptive nature in medical device regulation.“This guidance is really focused on a total product lifecycle approach,” Brooke explains.Good management practices govern traditional medical device development, so documenting the development process in pre-market submissions is not as critical. AI model development is different because the model can evolve once in service.“There's a level of information that's necessary in submissions for AI-based technologies that we haven't had to provide to the FDA before,” Brooke says. “They want a lot of information,” Brooke says. “That's an area I think may be problematic because a lot of that is somewhat trade secret.”AI-specific guidance touches almost every aspect of a company's submission, from risk assessment to labeling to cybersecurity. Brooke highlighted how the FDA's approach to AI data management could change development practices to ensure the independence of training and validation data sets. For example, companies must separate their clinical sites geographically and temporally.“This guidance gets into the weeds,” Brooke says. “It's important for companies to understand this if they're developing an AI-based product.”Data that made the difference:In addition to discussing the FDA's proposed AI regulations, Brooke discusses the challenges companies face in bringing AI-powered medical devices to market.“If you take away anything from this podcast,” Brooke says, “it's that there's a lot of burden associated with developing an AI-based medical device. If you don't need to, then I wouldn't recommend doing it.”Slow and steady wins the race. Do your homework, plan for the FDA review, and then engage the agency at the right time to get them on board.Thoroughly characterize your data sources. Devices like ECGs can vary by vendor, model, site location, patient, and many other factors. The FDA wants to know how this variability could affect the downstream AI model.Develop a strong clinical validation plan. The FDA will limit claims and require disclosures when a device that performs well overall underperforms among certain patient groups.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In this “back to basics” mini-series, Dr LaShanta Brice will discuss the clinical utility of the three most common parameters tested in the lab, the PT, APTT and Fibrinogen. Today we are going to cover the Prothrombin Time! We will discover why an order for a PT would be received by the lab, generally why the PT is used in practice and some emerging trends particularly when considering the INR clinic. Happy listening! Literature source: CLSI H47 One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test     Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Episode: 3014 Measuring Almost Nothing.  Today, we measure almost nothing.

Rua Gold. announced the commencement of drilling at the Cumberland gold camp drill target. Maple Gold Mines reported initial assay results from the first five drill holes completed during the 10,000-metre winter drill campaign  at its 100%-owned Douay Gold Project in Québec. West Point Gold announced the most recent drill results from its ongoing drill program at the Tyro Main Zone of the Gold Chain Project in Arizona. GFG Resources announced a private placement of premium flow-through units to raise gross proceeds of up to C$2.5 million. Los Andes Copper is pleased to announce that the Company has expanded its land package by obtaining first-priority exploration claims over new areas within and adjacent to the current property boundaries for Los Andes' Vizcachitas copper project in Chile.This episode of Mining Stock Daily is brought to you by…Integra Resources. Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.comThe Mining Stock Daily morning briefing is produced by Clear Commodity Network. It is distributed throughout the world through your podcast network of choice, and by our friends at the Junior Mining Network. 

On this weeks episode Brendan sits down with Patrick Hannington, a professor in the School of Public Health at the University of Alberta. His interests are at the interface between animals, parasites, and freshwater environments, including Prussian carp, a species capable of gynogesis, a reproductive technique that involves cloning and sperm stealing!  Patrick and Brendan discuss Prussian Carp, eDNA assay development, genetics, and assay validation. Recently, Patrick and his research group have been working to develop and implement a decentralized environmental DNA surveillance network to inform our understanding of invasive species, like Prussian carp and invasive mussels, in Western Canada. You can check out his labs work here: https://www.ualberta.ca/en/public-health/research/faculty-features/hanington.html Check out his teams swimmer's itch page here: https://swimmersitch.info/    Main Point: Don't forget the value of basic science!   Get in touch with us! The Fisheries Podcast is on Facebook, Bluesky, and Instagram: @FisheriesPod  Become a Patron of the show: https://www.patreon.com/FisheriesPodcast Buy podcast shirts, hoodies, stickers, and more: https://teespring.com/stores/the-fisheries- podcast-fan-shop Thanks as always to Andrew Gialanella for the fantastic intro/outro music. The Fisheries Podcast is a completely independent podcast, not affiliated with a larger organization or entity. Reference to any specific product or entity does not constitute an endorsement or recommendation by the podcast. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by the hosts are those of that individual and do not necessarily reflect the view of any entity that those individuals are affiliated in other capacities (such as employers).

Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.Speaker 3: (00:32) Would you mind telling us a little bit about yourself and your background? Speaker 3: (01:58) Would you give us an overview of membranous nephropathy?  Speaker 3: (07:14) Could you tell us a little bit about this new assay? Speaker 3: (14:29) Could you give a little example of how a clinician might use this information to treat their patients differently than how they would've in the past?   

In this episode of the Epigenetics Podcast, we talked with Vijay Ramani from the Gladstone Institute to talk about his work on Single-Molecule Adenine Methylated Oligonucleosome Sequencing Assay (SAMOSA). Our discussion starts with Vijay Ramani's impactful contributions to the field during his time in Jay Shendure's lab, where he worked on several innovative methods, including RNA proximity ligation. This project was conceived during his graduate studies, aiming to adapt techniques from DNA research to investigate RNA structures—a largely unexplored area at the time. We delved into the nuances of his experiences in graduate school, emphasizing how critical it was to have mentors who provided room for creativity and autonomy in experimental design. Dr. Ramani then shares insights about his foray into developing more refined methodologies, such as in-situ DNA Hi-C, a revolutionary protocol tailored for three-dimensional genomic mapping. He explained the rationale behind his projects, comparing the outcomes with contemporaneous advancements in methods like Micro-C. The discussion highlighted the importance of understanding enzyme bias in chromatin studies and the need for meticulous experimental design to ensure the validity of biological interpretations. We further explored exciting advancements in single-cell genomics, specifically Ramani's work on developing sci-Hi-C. This innovative technique leverages combinatorial indexing to allow high-resolution mapping of chromatin architecture at the single-cell level, a significant leap forward in understanding the complexities of gene regulation. As we progress, Ramani detailed his transition from graduate student to independent investigator starting his own lab. He elaborated on the challenges and excitements associated with establishing his research focus in chromatin structure and function using advanced sequencing technologies. Employing various strategies, including the innovative SAMOSA assay, his research seeks to elucidate the mechanisms by which chromatin structure influences transcriptional regulation. We also discussed the heterogeneity of chromatin and its implications for gene expression. Ramani provided a fascinating perspective on how variations in chromatin structure could affect gene activity, highlighting potential avenues for future research that aims to untangle the complex dynamics at play in both healthy and diseased states.   References Ramani, V., Cusanovich, D., Hause, R. et al. Mapping 3D genome architecture through in situ DNase Hi-C. Nat Protoc 11, 2104–2121 (2016). https://doi.org/10.1038/nprot.2016.126 Nour J Abdulhay, Colin P McNally, Laura J Hsieh, Sivakanthan Kasinathan, Aidan Keith, Laurel S Estes, Mehran Karimzadeh, Jason G Underwood, Hani Goodarzi, Geeta J Narlikar, Vijay Ramani (2020) Massively multiplex single-molecule oligonucleosome footprinting eLife 9:e59404. https://doi.org/10.7554/eLife.59404 Abdulhay, N.J., Hsieh, L.J., McNally, C.P. et al. Nucleosome density shapes kilobase-scale regulation by a mammalian chromatin remodeler. Nat Struct Mol Biol 30, 1571–1581 (2023). https://doi.org/10.1038/s41594-023-01093-6 Nanda, A.S., Wu, K., Irkliyenko, I. et al. Direct transposition of native DNA for sensitive multimodal single-molecule sequencing. Nat Genet 56, 1300–1309 (2024). https://doi.org/10.1038/s41588-024-01748-0   Related Episodes Epigenetic Mechanisms in Genome Regulation and Developmental Programming (James Hackett) Chromatin Profiling: From ChIP to CUT&RUN, CUT&Tag and CUTAC (Steven Henikoff) Split-Pool Recognition of Interactions by Tag Extension (SPRITE) (Mitch Guttman)   Contact Epigenetics Podcast on X Epigenetics Podcast on Instagram Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Epigenetics Podcast on Threads Active Motif on X Active Motif on LinkedIn Email: podcast@activemotif.com